Search

Your search keyword '"Domblides, Charlotte"' showing total 227 results

Search Constraints

Start Over You searched for: Author "Domblides, Charlotte" Remove constraint Author: "Domblides, Charlotte"
227 results on '"Domblides, Charlotte"'

Search Results

1. Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort

2. Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study

3. Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltration

6. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events

8. Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)

10. Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target.

15. Human NLRC4 promotes cancer survival and is associated to type-I interferon signaling and immune infiltration

16. Real-World Efficacy of the Dabrafenib-Trametinib (D-T) Combination in Braf V600e-Mutated Metastatic Non-Small Cell Lung Cancer (Nsclc): Results from the Ifct-2004 Blade Cohort

18. Safety of immune checkpoint inhibitor rechallenge after severe immune-related adverse events: a retrospective analysis.

22. Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice

23. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

27. How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma.

34. An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives

37. Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

39. No impact of psychosocial stress on glioblastoma development

40. Clinical Impact of STK11 Mutation in Advanced-Stage Non-Small-Cell Lung Cancer

41. No Impact of Psychosocial Stress on Glioblastoma Development

42. Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation

45. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

46. Human γδ T cell sensing of AMPK-dependent metabolic tumor reprogramming through TCR recognition of EphA2

48. Management of Immune Checkpoint Inhibitor Toxicities

49. Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

Catalog

Books, media, physical & digital resources